Literature DB >> 6300251

Quantification of natural cytotoxicity by human lymphocyte subpopulations isolated by density: heterogeneity of the effector cells.

E T Bloom, E L Korn.   

Abstract

Natural cell mediated cytotoxicity has been expressed as percent cytotoxicity, as the slope of the titration curve obtained by testing different effector: target cell ratios, and as lytic units. Objections can be raised to each method as used. The present report involves the study of cytotoxicity by subpopulations of lymphocytes obtained by Percoll density gradient centrifugation. The subpopulations vary greatly in cytotoxic activity, making accurate comparisons by traditional means difficult. A method was therefore developed for making objective comparisons between activities of subpopulations of lymphocytes. Cytotoxicity titration curves, which were sigmoidal on linear-linear plots, were found to best fit the sigmoidal curves described by the Von Krogh equation. A best fitting scale family of curves having the identical maximum cytotoxicity and shape parameter was fitted simultaneously to cytotoxicity measurements obtained by titrating all subpopulations of effector cells obtained from each patient. Values expressing relative cytotoxicities were obtained from the ratios of the scale parameters of the different curves or by obtaining lytic units from the fitted curves. In addition to the enriched natural cytotoxic activity found among the lighter cells obtained by Percoll density gradient centrifugation, activity was also increased among cells sedimenting at the very bottom of the gradient. This was found in subpopulations of cells obtained from 16/21 gradients in tests against K562 and in subpopulations obtained from both of 2 gradients in tests against Daudi cells. These findings are consistent with the existence of at least 2 subpopulations of lymphocytes which can mediate natural cytotoxicity, and which are separable by density.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300251     DOI: 10.1016/0022-1759(83)90360-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass.

Authors:  E Montserrat; N Villamor; A Urbano-Ispizua; J M Ribera; M Lozano; J L Vives-Corrons; C Rozman
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

2.  Natural killer cell function is not diminished in the healthy aged and is proportional to the number of NK cells in the peripheral blood.

Authors:  G J Ligthart; H R Schuit; W Hijmans
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

3.  Human natural cytotoxic cells: distinctive membrane markers and patterns of reactivity.

Authors:  J Stankova; M Rola-Pleszczynski
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

4.  Hemacytotoxicity and natural killer lytic index: New parameters to evaluate natural killer cell immunity for clinical use in cancer.

Authors:  Hyung Gun Maeng; Su Jin Lee; Yun A Lee; Hye Jeong Lee; Young Joo Kim; Jong Kyun Lee; Jae Cheol Kim; Joungbum Choi
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

5.  The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes.

Authors:  H Umehara; E T Bloom
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

6.  Immunological surveillance against DNA-virus-transformed cells: correlations between natural killer cell cytolytic competence and tumor susceptibility of athymic rodents.

Authors:  J L Cook; A M Lewis
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

7.  Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity.

Authors:  K Imada; E T Bloom; H Nakajima; J A Horvath-Arcidiacono; G B Udy; H W Davey; W J Leonard
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.